Company / Total Assets
Jazz Pharmaceuticals Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$11.7B
FY2025
5-year range
$10.8B / $12.3B
FY2021-FY2025
Trend
-2.9%
vs FY2024
Sector context
#21 of 214
Health Care
What the data says
Among 214 Health Care companies, Jazz Pharmaceuticals is in the top 10% for total assets. Total Assets has fluctuated over the past 10 years, ranging from $4.8B in FY2016 to $12.3B in FY2021.
Based on SEC 10-K filings.
$11.7B in FY2025 with a 5-year CAGR of +12.3%. Top quartile in the Health Care sector.
Improved from $11.4B to $11.7B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +2.5%
- 5-Year CAGR
- +12.3%
- 10-Year CAGR
- -
Sector benchmark
Top 10% in Health CareTop 10% of 214This company $11.7B Sector average $7.5B
▼
+56.1% above sector average
Key checks
Key Insights
- 5-year CAGR of +12.3%, indicating consistent growth.
- In FY2025, total assets decreased 2.9% year-over-year.
- Ranks #21 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- Negative profit margin: -8.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $11.7B | -2.9% |
| FY2024 | $12.0B | +5.4% |
| FY2023 | $11.4B | +5.2% |
| FY2022 | $10.8B | -11.9% |
| FY2021 | $12.3B | +88.2% |
| FY2020 | $6.5B | +18.0% |
| FY2019 | $5.5B | +6.4% |
| FY2018 | $5.2B | +1.6% |
| FY2017 | $5.1B | +6.7% |
| FY2016 | $4.8B | +44.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026